Epigenetic Therapies Show Promise in Cancer Treatment

Strategic Insights -

Research from the SRM Institute of Science and Technology has highlighted the potential of epigenetic therapies in cancer treatment. According to the study, epigenetic changes, such as DNA methylation and histone modifications, play a key role in cancer development and progression. These changes can be reversed, making them attractive targets for therapeutic interventions. The study reviews the various types of epigenetic drugs, including DNA methyltransferase inhibitors, histone deacetylase inhibitors, and histone methyltransferase inhibitors, and discusses their mechanisms of action, therapeutic potential, and clinical applications in various types of cancer.

Key Takeaways:

  • Epigenetic changes, such as DNA methylation and histone modifications, are reversible and can be targeted for therapeutic interventions.
  • Epigenetic drugs, including DNA methyltransferase inhibitors, histone deacetylase inhibitors, and histone methyltransferase inhibitors, are being studied for their potential in cancer treatment.
  • These drugs can repress normal gene expression, reverse drug resistance, and make tumors penetrable to existing treatments.
  • Personalized epigenetic therapy has the potential to tailor treatment schedules and enhance medical outcomes.
  • The study highlights the challenges faced by epigenetic therapies, including drug toxicity, off-target effects, and drug resistance.

Statistics:

  • According to the study, epigenetic changes are involved in the development and progression of various types of cancer, including breast, lung, colorectal, and brain tumors, as well as hematological malignancies such as acute myeloid leukemia (AML) and multiple myeloma.
  • The study notes that epigenetic drugs have shown promise in preclinical studies, but further research is needed to overcome limitations and develop effective combination strategies.
  • The study also highlights the potential of combining epigenetic therapy with conventional treatments, immunotherapy, and targeted therapy.

Sources:

  • Epidrugs in cancer: mechanisms, applications, and future direction. Clinical and Translational Oncology, 2025.
  • SRM Institute of Science and Technology, Kattankulathur, Chennai, Tamil Nadu, 603203, India.
  • Springer Int Publ Ag, Gewerbestrasse 11, Cham, Ch-6330, Switzerland.